Omega-3 (DHA)vsPEA (Palmitoylethanolamide)

DHA is a structural component of neuronal phospholipids (particularly phosphatidylethanolamine and phosphatidylserine in synaptic membranes), maintaining membrane fluidity which is essential for G-protein-coupled receptor function, ion channel gating, and synaptic vesicle fusion. DHA is metabolized by 15-lipoxygenase to specialized pro-resolving mediators (SPMs) including neuroprotectin D1 (NPD1), which actively resolve neuroinflammation by reducing NF-kappaB activation and pro-inflammatory cytokine production. DHA supports BDNF expression through modulation of the CREB pathway and promotes synaptic plasticity by enhancing long-term potentiation (LTP) and dendritic spine density. It also influences neurotransmitter receptor conformation and binding efficiency. Deficiency impairs membrane signaling, increases neuroinflammation, and accelerates cognitive decline.

PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.